Day: March 18, 2024

Zurich, March 18th, 2024 – The Switzerland-based protocol Liqwid Finance, in partnership with the issuer Issuance.Swiss AG, is launching CASL, an innovative ETP in the world of staking digital assets. CASL not only captures the performance of the underlying ADA, managed by the Cardano Foundation, but also the interest earned by staking the token. Distributed as an ETP (Exchange Traded Product), the product is accessible to all kind of investors from Thursday last on the Zurich stock exchange, the SIX Swiss Exchange (ISIN code CH1327686056 – Ticker CASL). For Florian Volery, co-founder of Liqwid Finance, “CASL offers all the advantages of traditional and decentralized finance. It’s a low-cost, liquid, institutional-quality product”. He has designed this ETP which, not only follows the developments of the ADA...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 18, 2024Idorsia Ltd (SIX: IDIA) today announced that it has successfully closed the transaction with Viatris Inc. (NASDAQ: VTRS), a global healthcare company, for the global research and development collaboration, focused on the development and commercialization of two innovative compounds, selatogrel and cenerimod, discovered by Idorsia. The upfront consideration of USD 350 million has now been fully paid by Viatris to Idorsia. Further details will be provided with the combined Full Year 2023 and First Quarter 2024 financial reporting on April 25th. The selatogrel and cenerimod programs will be discussed at an upcoming R&D day of our partner Viatris. Notes to the editor About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned...

Press release – inside informationBiotalys and Novonesis have entered into an agreement to advance EVOCA NG – the next generation of Biotalys’ product candidate EVOCA™* – to the final stage of development. Pending success in this final development stage, the agreement secures Novonesis as the global manufacturing partner for EVOCA NG, leveraging its leading fermentation capabilities. Biotalys also grants Novonesis the rights to distribute and sell EVOCA NG in select crops outside of the United States, in exchange for royalty payments.Ghent, BELGIUM , March 18, 2024 (GLOBE NEWSWIRE) —  – Biotalys (Euronext – BTLS), an Agricultural Technology (AgTech) company pioneering protein-based biocontrol solutions for sustainable crop protection, and Novonesis, a global leader in biosolutions, have unveiled a comprehensive,...

Stores and JOANN.com Remain Open; Company Continues to Operate as Usual Vendors, Landlords and Other General Unsecured Creditors Are Unimpaired Company Expects to Reduce Approximately $505 Million in Funded Debt Implementing Prepackaged Financial Recapitalization Plan on Expedited Basis HUDSON, Ohio, March 18, 2024 (GLOBE NEWSWIRE) — JOANN Inc. (NASDAQ: JOAN) (“JOANN” or the “Company”), the nation’s category leader in sewing and fabrics with one of the largest arts and crafts offerings, today announced that it has entered into a Transaction Support Agreement (“TSA” or “Agreement”) with a majority of its financial stakeholders and additional industry financing parties to strengthen the Company’s financial position. In connection with the TSA, the Company has received commitments for approximately $132 million in new financing and...

Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI®, the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic solid tumors Fennec will receive €40 million in upfront and up to €210 million in additional commercial and regulatory milestones, and tiered royalties up to the mid-twenties Enhances Norgine’s commitment to bringing transformative therapies to patients in Europe, U.K., Australia, and New Zealand who currently do not have access to a therapy to treat this life altering condition RESEARCH TRIANGLE PARK, N.C. and UXBRIDGE, United Kingdom, March 17, 2024 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical...